ENTtoday
  • Home
  • COVID-19
  • Practice Focus
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Departments
    • Issue Archive
    • TRIO Best Practices
      • Allergy
      • Facial Plastic/Reconstructive
      • Head and Neck
      • Laryngology
      • Otology/Neurotology
      • Pediatric
      • Rhinology
      • Sleep Medicine
    • Career Development
    • Case of the Month
    • Everyday Ethics
    • Health Policy
    • Legal Matters
    • Letter From the Editor
    • Medical Education
    • Online Exclusives
    • Practice Management
    • Resident Focus
    • Rx: Wellness
    • Special Reports
    • Tech Talk
    • Viewpoint
    • What’s Your O.R. Playlist?
  • Literature Reviews
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Events
    • Featured Events
    • TRIO Meetings
  • Contact Us
    • About Us
    • Editorial Board
    • Triological Society
    • Advertising Staff
    • Subscribe
  • Advertise
    • Place an Ad
    • Classifieds
    • Rate Card
  • Search

Avastin Treatment for Hereditary Hemorrhagic Telangiectasia Epistaxis

by Sue Pondrom • February 1, 2010

  • Tweet
  • Email
Print-Friendly Version

Can the vascular endothelial growth factor (VEGF) inhibitor bevacizumab (Avastin) treat hereditary hemorrhagic telangiectasia (HHT) epistaxis?

Background: HHT is an autosomal dominant disorder involving abnormal blood vessel development. An estimated 90 percent of HHT patients have epistaxis which can lead to significant blood loss requiring IV iron, emergency room visits and blood transfusions. Surgical outcomes are generally poor. VEGF has recently been found to be elevated in HHT patients. Bevacizumab (Avastin) is a recombinant, humanized, monoclonal antibody that binds to and inhibits the activity of VEGF.

You Might Also Like

  • Bevacizumab Therapy Effective for Hereditary Hemorrhagic Telangiectasia
  • Is Bevacizumab Effective for Reducing Epistaxis in Hereditary Hemorrhagic Telangiectasia?
  • Epistaxis Severity in Pediatric HHT Patients Is Typically Mild
  • Systemic Bevacizumab Promising for Treatment-Resistant Recurrent Respiratory Papillomatosis
Explore This Issue
February 2010

Study design: Case report of a 45-year-old male with HHT and frequent epistaxis.

Setting: The patient’s epistaxis began prior to 10 years of age. With frequent nosebleeds, anemia and varying hemoglobin levels, he sought treatment at the University of California, San Diego nasal dysfunction clinic.

Synopsis: After local anesthesia, the patient was injected submucosally with 100 mg of bevacizumab into both anterior nasal cavities without injection into the cartilaginous septum. The patient had no difficulties and within a week all nasal bleeding stopped. At the end of four months, however, the bleeding resumed.

A total of 50 mg of bevacizumab was diluted in 5 mL of normal saline. For two consecutive weeks following nasal irrigation with hypertonic saline, 0.1 mL of the spray was delivered into each nostril twice a day. After four days, the epistaxis ceased. Following seven days, bleeding was reduced to less than once a week. Between three and four months, the epistaxis resumed.

The patient elected to pursue a second course of topical treatment. Bleeding once again ceased and has remained minimal for 2.5 months.

Bottom line: If VEGF plays a role in the development of the telangiectasias that occur in HHT patients, bevacizumab may be useful in their treatment.

Citation: Davidson TM, Olitsky SE, Wei JL. Hereditary hemorrhagic telangiectasia/Avastin. The Laryngoscope. 2009;120(2):432-435.

Filed Under: Literature Reviews, Practice Focus, Rhinology, Rhinology Tagged With: Avastin, VEGFIssue: February 2010

You Might Also Like:

  • Bevacizumab Therapy Effective for Hereditary Hemorrhagic Telangiectasia
  • Is Bevacizumab Effective for Reducing Epistaxis in Hereditary Hemorrhagic Telangiectasia?
  • Epistaxis Severity in Pediatric HHT Patients Is Typically Mild
  • Systemic Bevacizumab Promising for Treatment-Resistant Recurrent Respiratory Papillomatosis

The Triological SocietyENTtoday is a publication of The Triological Society.

The Laryngoscope
Ensure you have all the latest research at your fingertips; Subscribe to The Laryngoscope today!

Laryngoscope Investigative Otolaryngology
Open access journal in otolaryngology – head and neck surgery is currently accepting submissions.

Classifieds

View the classified ads »

TRIO Best Practices

View the TRIO Best Practices »

Top Articles for Residents

  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Why More MDs, Medical Residents Are Choosing to Pursue Additional Academic Degrees
  • What Physicians Need to Know about Investing Before Hiring a Financial Advisor
  • Tips to Help You Regain Your Sense of Self
  • Should USMLE Step 1 Change from Numeric Score to Pass/Fail?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Vertigo in the Elderly: What Does It Mean?
    • Experts Delve into Treatment Options for Laryngopharyngeal Reflux
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Otolaryngologists Have a Major Role to Play in Treating COVID-19 Long-Haulers
    • Vertigo in the Elderly: What Does It Mean?
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Eustachian Tuboplasty: A Potential New Option for Chronic Tube Dysfunction and Patulous Disease
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Podcasts Becoming More Popular Method of Education for Otolaryngologists
    • How to Embrace Optimism in the Midst of the COVID-19 Pandemic
    • Tips on How to Approach Conversations with Patients about the COVID-19 Vaccine
    • Steps You Should Take to Protect Your Voice and Hearing During Telemedicine Sessions
    • Routine Postoperative Adjunct Treatments Unnecessary for Idiopathic Cerebrospinal Fluid Leaks

Polls

Have you spoken with your patients about receiving the COVID-19 vaccine?

View Results

Loading ... Loading ...
  • Polls Archive
  • Home
  • Contact Us
  • Advertise
  • Privacy Policy
  • Terms of Use

Visit: The Triological Society • The Laryngoscope • Laryngoscope Investigative Otolaryngology

Wiley
© 2021 The Triological Society. All Rights Reserved.
ISSN 1559-4939

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.